To this end, the breast cancer cell lines with or without PAK1 amplification and/or overexpression, were treated with vehicle or PF-3758309, a small molecule inhibitor of Group A and Group B PAKs [19], or transfected with PAK1 targeting siRNAs, and DNA damage was induced with cisplatin. This evidence concerns the gene PAK1 and breast cancer.